An Open-Label,Randomized Phase 3 trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Administered By

Awarded By

Contributors

Start/End

  • November 1, 2015 - May 21, 2018